Metformin for advanced colorectal cancer with chemotherapy
Part of Cancer clinical trials.
This trial tests whether adding metformin (a diabetes drug) to standard chemotherapy (FOLFIRI) and targeted therapy can help people with metastatic colorectal cancer live longer or respond better to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 90 years old.
- You have metastatic colorectal cancer and your doctor plans FOLFIRI chemotherapy for you.
- If female, you are not pregnant, not breastfeeding, and willing to use birth control during the study.
- You do not have serious heart, kidney, liver, or other major disease problems controlled by your doctor.
- You are not allergic to metformin or any study drugs.
- You are able to take medicines as instructed and sign a consent form.
- Your blood sugar level is above 80 mg/dL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
This Phase 2 trial studies whether metformin, added to standard hormone-blocking treatment, can improve outcomes for men with newly diagnosed metastatic hormone-sensitive prostate cancer. It’s meant to test benefits of targeting metabolism in addition to prostate cancer hormone therapy.
This study tests if metformin, a common diabetes medicine, can help reduce insulin resistance in women who finished chemotherapy for early-stage breast cancer. It aims to improve long-term health and prevent future problems.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests if taking metformin (a diabetes pill) before standard chemoradiation can make esophageal cancer respond better. You take metformin for 2 weeks before starting standard treatment, and doctors will check your tumor with two endoscopies to see how it changes.
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
Hear when a new Progression-Free Survival trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.